Glomerular diseases: Registries and clinical trials

Marva M. Moxey-Mims, Michael F. Flessner, Lawrence Holzman, Frederick J. Kaskel, John R. Sedor, William E. Smoyer, Aliza M. Thompson, Lynne Yao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nephrology has conducted few high-quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for primary or inflammatory glomerular diseases. There are overarching process issues that affect the conduct of all clinical trials, but there are also some specialty-specific issues. Within nephrology, primary glomerular diseases are rare, making adequate recruitment for meaningful trials difficult. Nephrologists need better ways, beyond histopathology, to phenotype patients with glomerular diseases and stratify the risk for progression to ESRD. Rigorous trial design is needed for the testing of new therapies, where most patients with glomerular diseases are offered the opportunity to enroll in a clinical trial if standard therapies have failed or are lacking. Training programs to develop a core group of kidney specialists with expertise in the design and implementation of clinical trials are also needed. Registries of patients with glomerular disease and observational studies can aid in the ability to determine realistic estimates of disease prevalence and inform trial design through a better understanding of the natural history of disease. Some proposed changes to the Common Rule, the federal regulations governing the ethical conduct of research involving humans, and the emerging use of electronic health records may facilitate the efficiency of initiating multicenter clinical trials. Collaborations among academia, government scientific and regulatory agencies, industry, foundations, and patient advocacy groups can accelerate therapeutic development for these complex diseases.

Original languageEnglish (US)
Pages (from-to)2234-2243
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume11
Issue number12
DOIs
StatePublished - 2016

Fingerprint

Registries
Clinical Trials
Nephrology
Patient Advocacy
Electronic Health Records
Therapeutics
Rare Diseases
Multicenter Studies
Chronic Kidney Failure
Observational Studies
Industry
Phenotype
Kidney
Education
Research

Keywords

  • Chronic
  • Clinical trial
  • Cooperative Behavior
  • Electronic Health Records
  • Foundations
  • Glomerular disease
  • Government
  • Humans
  • Kidney
  • Kidney Failure
  • Kidney Glomerulus
  • Nephrology
  • Patient Advocacy
  • Phenotype
  • Prevalence
  • Registries
  • Registries
  • Research
  • Science
  • Specialization

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Moxey-Mims, M. M., Flessner, M. F., Holzman, L., Kaskel, F. J., Sedor, J. R., Smoyer, W. E., ... Yao, L. (2016). Glomerular diseases: Registries and clinical trials. Clinical Journal of the American Society of Nephrology, 11(12), 2234-2243. https://doi.org/10.2215/CJN.00540116

Glomerular diseases : Registries and clinical trials. / Moxey-Mims, Marva M.; Flessner, Michael F.; Holzman, Lawrence; Kaskel, Frederick J.; Sedor, John R.; Smoyer, William E.; Thompson, Aliza M.; Yao, Lynne.

In: Clinical Journal of the American Society of Nephrology, Vol. 11, No. 12, 2016, p. 2234-2243.

Research output: Contribution to journalArticle

Moxey-Mims, MM, Flessner, MF, Holzman, L, Kaskel, FJ, Sedor, JR, Smoyer, WE, Thompson, AM & Yao, L 2016, 'Glomerular diseases: Registries and clinical trials', Clinical Journal of the American Society of Nephrology, vol. 11, no. 12, pp. 2234-2243. https://doi.org/10.2215/CJN.00540116
Moxey-Mims, Marva M. ; Flessner, Michael F. ; Holzman, Lawrence ; Kaskel, Frederick J. ; Sedor, John R. ; Smoyer, William E. ; Thompson, Aliza M. ; Yao, Lynne. / Glomerular diseases : Registries and clinical trials. In: Clinical Journal of the American Society of Nephrology. 2016 ; Vol. 11, No. 12. pp. 2234-2243.
@article{00a1ce78866b4d329b193239aea69755,
title = "Glomerular diseases: Registries and clinical trials",
abstract = "Nephrology has conducted few high-quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for primary or inflammatory glomerular diseases. There are overarching process issues that affect the conduct of all clinical trials, but there are also some specialty-specific issues. Within nephrology, primary glomerular diseases are rare, making adequate recruitment for meaningful trials difficult. Nephrologists need better ways, beyond histopathology, to phenotype patients with glomerular diseases and stratify the risk for progression to ESRD. Rigorous trial design is needed for the testing of new therapies, where most patients with glomerular diseases are offered the opportunity to enroll in a clinical trial if standard therapies have failed or are lacking. Training programs to develop a core group of kidney specialists with expertise in the design and implementation of clinical trials are also needed. Registries of patients with glomerular disease and observational studies can aid in the ability to determine realistic estimates of disease prevalence and inform trial design through a better understanding of the natural history of disease. Some proposed changes to the Common Rule, the federal regulations governing the ethical conduct of research involving humans, and the emerging use of electronic health records may facilitate the efficiency of initiating multicenter clinical trials. Collaborations among academia, government scientific and regulatory agencies, industry, foundations, and patient advocacy groups can accelerate therapeutic development for these complex diseases.",
keywords = "Chronic, Clinical trial, Cooperative Behavior, Electronic Health Records, Foundations, Glomerular disease, Government, Humans, Kidney, Kidney Failure, Kidney Glomerulus, Nephrology, Patient Advocacy, Phenotype, Prevalence, Registries, Registries, Research, Science, Specialization",
author = "Moxey-Mims, {Marva M.} and Flessner, {Michael F.} and Lawrence Holzman and Kaskel, {Frederick J.} and Sedor, {John R.} and Smoyer, {William E.} and Thompson, {Aliza M.} and Lynne Yao",
year = "2016",
doi = "10.2215/CJN.00540116",
language = "English (US)",
volume = "11",
pages = "2234--2243",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - Glomerular diseases

T2 - Registries and clinical trials

AU - Moxey-Mims, Marva M.

AU - Flessner, Michael F.

AU - Holzman, Lawrence

AU - Kaskel, Frederick J.

AU - Sedor, John R.

AU - Smoyer, William E.

AU - Thompson, Aliza M.

AU - Yao, Lynne

PY - 2016

Y1 - 2016

N2 - Nephrology has conducted few high-quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for primary or inflammatory glomerular diseases. There are overarching process issues that affect the conduct of all clinical trials, but there are also some specialty-specific issues. Within nephrology, primary glomerular diseases are rare, making adequate recruitment for meaningful trials difficult. Nephrologists need better ways, beyond histopathology, to phenotype patients with glomerular diseases and stratify the risk for progression to ESRD. Rigorous trial design is needed for the testing of new therapies, where most patients with glomerular diseases are offered the opportunity to enroll in a clinical trial if standard therapies have failed or are lacking. Training programs to develop a core group of kidney specialists with expertise in the design and implementation of clinical trials are also needed. Registries of patients with glomerular disease and observational studies can aid in the ability to determine realistic estimates of disease prevalence and inform trial design through a better understanding of the natural history of disease. Some proposed changes to the Common Rule, the federal regulations governing the ethical conduct of research involving humans, and the emerging use of electronic health records may facilitate the efficiency of initiating multicenter clinical trials. Collaborations among academia, government scientific and regulatory agencies, industry, foundations, and patient advocacy groups can accelerate therapeutic development for these complex diseases.

AB - Nephrology has conducted few high-quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for primary or inflammatory glomerular diseases. There are overarching process issues that affect the conduct of all clinical trials, but there are also some specialty-specific issues. Within nephrology, primary glomerular diseases are rare, making adequate recruitment for meaningful trials difficult. Nephrologists need better ways, beyond histopathology, to phenotype patients with glomerular diseases and stratify the risk for progression to ESRD. Rigorous trial design is needed for the testing of new therapies, where most patients with glomerular diseases are offered the opportunity to enroll in a clinical trial if standard therapies have failed or are lacking. Training programs to develop a core group of kidney specialists with expertise in the design and implementation of clinical trials are also needed. Registries of patients with glomerular disease and observational studies can aid in the ability to determine realistic estimates of disease prevalence and inform trial design through a better understanding of the natural history of disease. Some proposed changes to the Common Rule, the federal regulations governing the ethical conduct of research involving humans, and the emerging use of electronic health records may facilitate the efficiency of initiating multicenter clinical trials. Collaborations among academia, government scientific and regulatory agencies, industry, foundations, and patient advocacy groups can accelerate therapeutic development for these complex diseases.

KW - Chronic

KW - Clinical trial

KW - Cooperative Behavior

KW - Electronic Health Records

KW - Foundations

KW - Glomerular disease

KW - Government

KW - Humans

KW - Kidney

KW - Kidney Failure

KW - Kidney Glomerulus

KW - Nephrology

KW - Patient Advocacy

KW - Phenotype

KW - Prevalence

KW - Registries

KW - Registries

KW - Research

KW - Science

KW - Specialization

UR - http://www.scopus.com/inward/record.url?scp=85021716380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021716380&partnerID=8YFLogxK

U2 - 10.2215/CJN.00540116

DO - 10.2215/CJN.00540116

M3 - Article

C2 - 27672219

AN - SCOPUS:85021716380

VL - 11

SP - 2234

EP - 2243

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 12

ER -